Related Experiment Video
Updated: Aug 23, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Cerivastatin does not prevent oxidative injury of human aortic endothelial cells
Sharif Al-Ruzzeh1, Ilona Schmidt, Koki Nakamura
1Department of Cardiothoracic Surgery, Harefield Hospital, Middlesex UB9 6JH, United Kingdom.
Insights
Cerivastatin, a statin, did not protect human aortic endothelial cells from oxidative stress. This study found no evidence that cerivastatin prevents injury caused by hydrogen peroxide or superoxide anions.
Area of Science:
- Cardiovascular Research
- Cell Biology
- Pharmacology
Background:
- Statins (HMG-CoA reductase inhibitors) are known for anti-atherogenic properties.
- Statins' potential to mitigate ischemia-reperfusion injury via antioxidant effects is debated.
- Oxidative stress plays a role in vascular injury.
Purpose of the Study:
- To investigate if cerivastatin protects human aortic endothelial cells (HAEC) from oxidative stress-induced injury.
- To determine if cerivastatin exhibits antioxidant capabilities in vascular endothelial cells.
Main Methods:
- HAEC were exposed to oxidative stress using hydrogen peroxide or diethylthiocarbamate.
- Cerivastatin (50 nM-1,000 nM) or N-acetyl-L-cysteine pretreatment was applied.
- Cell viability (MTT assay) and morphology were assessed.
Main Results:
- Cerivastatin alone did not affect HAEC viability or morphology.
- Cerivastatin pretreatment did not protect HAEC against hydrogen peroxide-induced cell death.
- Neither cerivastatin nor N-acetyl-L-cysteine protected HAEC from diethylthiocarbamate-induced injury.
Conclusions:
- Cerivastatin does not protect cultured human aortic endothelial cells against oxidative stress.
- The proposed antioxidant or cytoprotective effects of cerivastatin in this context were not demonstrated.
- Further research is needed to clarify the role of statins in mitigating oxidative stress-related vascular damage.
Abstract:
The anti-atherogenic properties of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been well established in several circulatory beds. Increasing evidence suggests that statins may help attenuate ischemia-reperfusion injury, a beneficial effect that may be related to the antioxidant capabilities of statins; however, this remains controversial. We performed this study to determine whether the HMG-CoA reductase inhibitor cerivastatin can prevent oxidative stress-induced injury in cultured human aortic endothelial cells (HAEC). The HAEC were subjected to oxidative stress in the absence and presence of increasing concentrations of cerivastatin (50 nM-1,000 nM). Oxidative stress was induced by increasing concentrations of hydrogen peroxide or endogenous superoxide anions generated by the inhibition of superoxide dismutase using diethylthiocarbamate (10 mM). Cell viability and mitochondrial activity were measured by mitochondria-dependent 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) conversion. Cell morphology was also examined using light microscopy. Exposing HAEC to cerivastatin for 24 hours had no effect on cell viability using both cell morphology and MTT conversion: the HAEC incubated in 100 nM cerivastatin had 90% +/- 2.2% viability of the control. As expected, hydrogen peroxide produced a concentration-dependent decrease in cell viability. Varying concentrations of cerivastatin pretreatment for < or = 18 hours showed no protection of HAEC against hydrogen peroxide-induced injury. As a positive control, the prototype antioxidant N-acetyl-L-cysteine was cytoprotective even with the highest hydrogen peroxide concentration. Neither cerivastatin nor N-acetyl-L-cysteine protected HAEC against diethylthiocarbamate-induced oxidative injury at any concentration. In this study, cerivastatin did not protect cultured HAEC against oxidative stress induced by hydrogen peroxide or diethylthiocarbamate.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis I: Introduction
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Coronary Artery Disease I: Introduction
